+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Immune Disorders Drugs Market Research Reports

Pemphigus Vulgaris - Pipeline Insight, 2025 - Product Thumbnail Image

Pemphigus Vulgaris - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Celiac Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Celiac Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
From
From
From
From
H 4 Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

H 4 Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
H 3 Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

H 3 Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
H 2 Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

H 2 Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
HIV Attachment Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

HIV Attachment Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
E-Selectin Inhibitor- Pipeline Insight, 2025 - Product Thumbnail Image

E-Selectin Inhibitor- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
NF-kappa B Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

NF-kappa B Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 90 Pages
  • Global
From
H Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

H Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 120 Pages
  • Global
From
Egg Allergy - Pipeline Insight, 2025 - Product Thumbnail Image

Egg Allergy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
RIPK1 Inhibitor - Pipeline Insights, 2025 - Product Thumbnail Image

RIPK1 Inhibitor - Pipeline Insights, 2025

  • Clinical Trials
  • April 2025
  • 50 Pages
  • Global
From
Neonatal Fc Receptor Antagonists- Pipeline Insight, 2025 - Product Thumbnail Image

Neonatal Fc Receptor Antagonists- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Complement C1s Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Complement C1s Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Complement C3 Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Complement C3 Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
PD-1 And PD-L1 Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

PD-1 And PD-L1 Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 200 Pages
  • Global
From
Mucopolysaccharidosis Type I- Pipeline Insight, 2025 - Product Thumbnail Image

Mucopolysaccharidosis Type I- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Immune Disorders Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs to treat immune system disorders. These drugs are used to treat a variety of conditions, including allergies, asthma, autoimmune diseases, and cancer. Immune Disorders Drugs are designed to target specific parts of the immune system, such as cytokines, antibodies, and T-cells, to reduce inflammation and improve the body's ability to fight off infection. The Immune Disorders Drugs market is highly competitive, with many large pharmaceutical companies competing for market share. Some of the major players in the market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are constantly researching and developing new drugs to treat immune system disorders, as well as improving existing treatments. Show Less Read more